NovoCure (Nasdaq:NVCR) - 주가, 뉴스 및 분석

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

NVCR 주식 개요

종양학 회사인 NovoCure Limited는 미국, 독일, 일본, 중화권 및 전 세계에서 고형 종양 암 치료를 위한 종양 치료 필드(TTFields) 장치의 개발, 제조 및 상용화에 종사하고 있습니다.

NVCR 기본 분석
눈송이 점수
가치 평가	3/6
미래 성장	1/6
과거 실적	0/6
재무 상태	4/6
배당금	0/6

보상

공정 가치 추정치보다 낮은 54.1% 에서 거래

수익은 연간 9.6% 증가할 것으로 예상됩니다.

위험 분석

현재 수익성이 없으며 향후 3년 동안 수익을 낼 것으로 예상되지 않습니다.

NovoCure Limited 경쟁사

Omnicell

NasdaqGS:OMCL

US$2.1b

Integra LifeSciences Holdings

NasdaqGS:IART

US$1.6b

NuVasive

NasdaqGS:NUVA

US$2.1b

Enovis

NYSE:ENOV

US$2.6b

가격 내역 및 성능

다음에 대한 모든 사상 최고가, 변동 및 가격 하락 요약 NovoCure
과거 주가
현재 주가	US$18.02
52주 최고치	US$24.74
52주 최저치	US$10.87
베타	0.69
11개월 변경	-5.26%
3개월 변경 사항	-19.27%
1년 변경 사항	-3.14%
33년 변화	-86.60%
5년 변화	-80.17%
IPO 이후 변화	-1.42%

최근 뉴스 및 업데이트

NovoCure Limited: A Post Q2 Analysis

Jul 26

Recent updates

Some Shareholders Feeling Restless Over NovoCure Limited's (NASDAQ:NVCR) P/S Ratio

Mar 03

NovoCure: Stay Cautious Amid Positive Signs

Jan 19

Does NovoCure (NASDAQ:NVCR) Have A Healthy Balance Sheet?

Nov 16

Is NovoCure (NASDAQ:NVCR) Weighed On By Its Debt Load?

Aug 13

Is NovoCure (NASDAQ:NVCR) A Risky Investment?

May 15

A Look At The Intrinsic Value Of NovoCure Limited (NASDAQ:NVCR)

Apr 24

Why NovoCure Limited (NASDAQ:NVCR) Could Be Worth Watching

Feb 10

Does NovoCure (NASDAQ:NVCR) Have A Healthy Balance Sheet?

Jan 16

NovoCure: See Past Market Myopia And Buy The Dip

Sep 27

Novocure creates new CNS focused franchise to renew growth in brain cancer business

Sep 21

Does NovoCure (NASDAQ:NVCR) Have A Healthy Balance Sheet?

Sep 09

NovoCure: Does The Reward Outweigh The Risk? I Believe So

Sep 09

NovoCure Q2 2022 Earnings Preview

Jul 27

주주 수익률

	NVCR	US Medical Equipment	US 마켓
7D	-0.3%	1.7%	1.2%
1Y	-3.1%	12.5%	25.9%

수익률 대 산업: NVCR 지난 1년 동안 10.3 %를 반환한 US Medical Equipment 업계보다 저조한 성과를 냈습니다.

수익률 대 시장: NVCR 지난 1년 동안 24.7 %를 반환한 US 시장보다 저조한 성과를 냈습니다.

가격 변동성

Is NVCR's price volatile compared to industry and market?
NVCR volatility
NVCR Average Weekly Movement	8.7%
Medical Equipment Industry Average Movement	8.4%
Market Average Movement	6.4%
10% most volatile stocks in US Market	15.2%
10% least volatile stocks in US Market	3.2%

안정적인 주가: NVCR 의 주가는 지난 3개월 동안 변동성이 심했습니다.

시간에 따른 변동성: NVCR 의 주간 변동성( 9% )은 지난 1년 동안 안정적인 모습을 보였습니다.

회사 소개

설립	직원	CEO	웹사이트
2000	1,453	Asaf Danziger	www.novocure.com

종양학 회사인 NovoCure Limited는 미국, 독일, 일본, 중화권 및 전 세계에서 고형 종양 암 치료를 위한 종양 치료 필드(TTFields) 장치의 개발, 제조 및 상용화에 종사하고 있습니다. 이 회사의 TTFields 기기에는 Optune Gio와 Optune Lua가 있습니다. 또한 뇌 전이, 위암, 교모세포종, 간암, 비소세포폐암, 췌장암, 난소암에 대한 TTFields 임상시험을 진행 중입니다.

NovoCure Limited 기본 사항 요약

NovoCure 의 수익과 매출은 시가총액과 어떻게 비교하나요?
NVCR 기본 통계
시가총액	US$1.95b
수익(TTM)	-US$168.70m
수익(TTM)	US$549.96m

3.5x

P/S 비율

-11.6x

P/E 비율

NVCR 주가가 과대평가되어 있나요?

공정 가치 및 가치 분석 보기

수익 및 수익

최신 수익 보고서의 주요 수익성 통계(TTM)
NVCR 손익 계산서(TTM)
수익	US$549.96m
수익 비용	US$132.19m
총 이익	US$417.77m
기타 비용	US$586.47m
수익	-US$168.70m

최근 보고된 수익

Jun 30, 2024

다음 수익 날짜

n/a

주당 순이익(EPS)	-1.56
총 마진	75.96%
순이익 마진	-30.67%
부채/자본 비율	180.6%

NVCR 의 장기적인 성과는 어땠나요?

과거 실적 및 비교 보기

NVCR 주식 개요

보상

위험 분석

NovoCure Limited 경쟁사

NasdaqGS:OMCL

US$2.1b

NasdaqGS:IART

US$1.6b

NasdaqGS:NUVA

US$2.1b

NYSE:ENOV

US$2.6b

가격 내역 및 성능

최근 뉴스 및 업데이트

Consensus estimates of losses per share improve by 15%

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

NovoCure Limited: A Post Q2 Analysis

NovoCure Limited(NasdaqGS:NVCR) dropped from Russell 1000 Dynamic Index

NovoCure Limited to Report Q2, 2024 Results on Jul 25, 2024

Chief Operating Officer exercised options to buy US$2.7m worth of stock.

Recent updates

Consensus estimates of losses per share improve by 15%

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

NovoCure Limited: A Post Q2 Analysis

NovoCure Limited(NasdaqGS:NVCR) dropped from Russell 1000 Dynamic Index

NovoCure Limited to Report Q2, 2024 Results on Jul 25, 2024

Chief Operating Officer exercised options to buy US$2.7m worth of stock.

Now 22% undervalued

Novocure Announces the Presentation of Clinical Data from the Phase 3 Metis Trial

Novocure Releases Topline Efficacy and Safety Data from the TIGER Study Investigating the Use of Tumor Treating Fields Therapy in the Treatment of Patients with Newly Diagnosed Glioblastoma in Germany

Now 22% undervalued

NovoCure Limited announced that it expects to receive $400 million in funding

NovoCure Limited Q1 Earnings: Core Business Accelerating

NovoCure Limited announced that it expects to receive $400 million in funding

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

NovoCure Limited Announces Results of the Metis Phase 3 Clinical Trial in Brain Metastases from Non-Small Cell Lung Cancer

NovoCure Limited, Annual General Meeting, Jun 05, 2024

New minor risk - Insider selling

New minor risk - Shareholder dilution

NovoCure (NASDAQ:NVCR) Has Debt But No Earnings; Should You Worry?

NovoCure Limited to Report Q1, 2024 Results on May 02, 2024

NovoCure: Sell The METIS-Inspired Rally

Price target increased by 8.8% to US$27.20

Some Shareholders Feeling Restless Over NovoCure Limited's (NASDAQ:NVCR) P/S Ratio

Full year 2023 earnings: EPS exceeds analyst expectations

NovoCure: Stay Cautious Amid Positive Signs

Novocure Announces FDA Acceptance of the PMA Application for TTFields Therapy in Non-Small Cell Lung Cancer

NovoCure Limited Announces Last Patient Enrolled in Phase 3 Trident Trial in Newly Diagnosed Glioblastoma

NovoCure Limited Announces Executive Changes

Novocure Announces Portfolio Prioritization and Strategic Restructuring Plan Focused on Near-Term Growth Drivers and an Accelerated Path to Profitability

Does NovoCure (NASDAQ:NVCR) Have A Healthy Balance Sheet?

Chief Financial Officer exercised options to buy US$231k worth of stock.

Third quarter 2023 earnings released: US$0.46 loss per share (vs US$0.25 loss in 3Q 2022)

NovoCure Limited to Report Q3, 2023 Results on Oct 26, 2023

NovoCure Limited(NasdaqGS:NVCR) dropped from FTSE All-World Index (USD)

Novocure Announces the Lancet Oncology Publishes Primary Data from Phase 3 Lunar Clinical Trial in Patients with Metastatic Non-Small Cell Lung Cancer After Platinum-Based Therapies

Price target decreased by 42% to US$35.17

Is NovoCure (NASDAQ:NVCR) Weighed On By Its Debt Load?

Price target decreased by 9.4% to US$60.33

Levi & Korsinsky Notifies NovoCure Limited Investors of a Class Action Lawsuit and Upcoming Deadline

New major risk - Revenue and earnings growth

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Novocure Announces Favorable Independent Data Monitoring Committee Recommendation to Continue Phase 3 Panova-3 Clinical Trial of Tumor Treating Fields Therapy in Pancreatic Cancer

NovoCure Limited to Report Q2, 2023 Results on Jul 27, 2023

Holzer & Holzer, LLC Files Lawsuit Against NovoCure Limited

Price target decreased by 16% to US$64.17

Zai Lab and Novocure Announces Lunar Phase 3 Clinical Trial Demonstrates Statistically Significant and Clinically Meaningful Extension in Overall Survival for Patients with Metastatic Non-Small Cell Lung Cancer After Platinum-Based Therapies

Is NovoCure (NASDAQ:NVCR) A Risky Investment?

Consensus EPS estimates fall by 31%

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Price target decreased by 20% to US$82.00

A Look At The Intrinsic Value Of NovoCure Limited (NASDAQ:NVCR)

Consensus EPS estimates fall by 12%

Chief Operating Officer notifies of intention to sell stock

Chief Operating Officer recently sold US$165k worth of stock

Consensus EPS estimates fall by 31%

Full year 2022 earnings released: US$0.88 loss per share (vs US$0.56 loss in FY 2021)

Novocure Announces Last Patient Enrolled in Pivotal PANOVA-3 Study of Tumor Treating Fields in Pancreatic Cancer

Why NovoCure Limited (NASDAQ:NVCR) Could Be Worth Watching

Novocure Announces Executive Changes